keyword
MENU ▼
Read by QxMD icon Read
search

Pharma

keyword
https://www.readbyqxmd.com/read/29448963/academic-medical-centers-as-innovation-ecosystems-to-address-population-omics-challenges-in-precision-medicine
#1
REVIEW
Patrick J Silva, Valerie M Schaibley, Kenneth S Ramos
While the promise of the Human Genome Project provided significant insights into the structure of the human genome, the complexities of disease at the individual level have made it difficult to utilize -omic information in clinical decision making. Some of the existing constraints have been minimized by technological advancements that have reduced the cost of sequencing to a rate far in excess of Moore's Law (a halving in cost per unit output every 18 months). The reduction in sequencing costs has made it economically feasible to create large data commons capturing the diversity of disease across populations...
February 15, 2018: Journal of Translational Medicine
https://www.readbyqxmd.com/read/29445569/glutathione-for-skin-lightening-a-regnant-myth-or-evidence-based-verity
#2
Sidharth Sonthalia, Abhijeet K Jha, Aimilios Lallas, Geraldine Jain, Deepak Jakhar
The recent hype surrounding the antimelanogenic properties of glutathione has resulted in physicians frequently administering it as a "wonder" drug for skin lightening and treatment of hyperpigmentation, especially in ethnic populations with darker skin tones. This phenomenon has seen a recent surge owing to aggressive marketing and capitalization of pharma-cosmeceutical companies. However, the unbridled and prodigal use of it, especially as a parenteral formulation, seems unjustified, given the lacunae in our knowledge about its antimelanogenic potential, limited clinical evidence favoring its role in skin lightening, and the statutory ban/advisory issued by certain federal agencies...
January 2018: Dermatology Practical & Conceptual
https://www.readbyqxmd.com/read/29445212/archimedes-principle-for-characterisation-of-recombinant-whole-cell-biocatalysts
#3
Steven Schmitt, Marcel Walser, Michael Rehmann, Sabine Oesterle, Sven Panke, Martin Held
The ability of whole cells to catalyse multistep reactions, often yielding synthetically demanding compounds later used by industrial biotech or pharma, makes them an indispensable tool of synthetic chemistry. The complex reaction network employed by cellular catalysts and the still only moderate predictive power of modelling approaches leaves this tool challenging to engineer. Frequently, large libraries of semi-rationally generated variants are sampled in high-throughput mode in order to then identify improved catalysts...
February 14, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29441957/smartlipids-%C3%A2-as-third-solid-lipid-nanoparticle-generation-stabilization-of-retinol-for-dermal-application
#4
Y Ding, S M Pyo, R H Müller
smartLipids® as the 3rd lipid nanoparticle generation are made from a complex lipid mixture. The chaotic particle matrix structure provides higher loading with actives and a firmer inclusion inside the particle matrix being more protective for chemically labile molecules. Thus, these particles were used to develop an optimized retinol formulation. As a new approach, the old concept of the core-shell SLN particles was combined with the novel smartLipids® technology as new stabilization model. Particles were produced by hot high pressure homogenization, loaded with increasing amounts of retinol (5%, 15%, 20%), and both the physical (size, crystallinity) and chemical stability were monitored...
December 1, 2017: Die Pharmazie
https://www.readbyqxmd.com/read/29441500/the-epidemiology-of-clostridium-difficile-infection-in-japan-a-systematic-review
#5
REVIEW
Thomas V Riley, Tomomi Kimura
To increase understanding of the epidemiology, risks, consequences and resource utilization of Clostridium difficile infection (CDI) in Japan, a systematic literature review was undertaken of relevant publications from January 2006 to November 2017. Using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and methods, 55 articles met the criteria for full review. The majority (58%) of studies were from a single site, with the most recent data from 2015. The incidence, reported prevalence and recurrence rate of CDI in Japan were 0...
February 13, 2018: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/29435909/efficacy-and-safety-of-teneligliptin-40%C3%A2-mg-in-type-2-diabetes-a-pooled-analysis-of-two-phase-iii-clinical-studies
#6
Takashi Kadowaki, Kazuyo Sasaki, Manabu Ishii, Miyuki Matsukawa, Yoshiteru Ushirogawa
INTRODUCTION: Teneligliptin, an antihyperglycemic agent belonging to the dipeptidyl peptidase-4 inhibitor class, is usually prescribed at a dose of 20 mg/day. In Japan, the dose can be increased to 40 mg/day if needed. We examined the treatment response when the teneligliptin dose was increased from 20 to 40 mg in a post hoc pooled analysis of data from two 52-week, open-label, phase III clinical trials of teneligliptin 20-40 mg/day as monotherapy or combination treatment in Japanese patients with type 2 diabetes...
February 12, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29433155/nutraceuticals-opening-the-debate-for-a-regulatory-framework
#7
REVIEW
Antonello Santini, Silvia Miriam Cammarata, Giacomo Capone, Angela Ianaro, Giancarlo Tenore, Luca Pani, Ettore Novellino
Currently, nutraceuticals do not have a specific definition distinct from those of other food-derived categories, e.g., food supplements, herbal products, pre- and probiotics, functional foods, and fortified foods. Many studies have led to an understanding of the potential mechanisms of action of pharmaceutically active components contained in food that may improve health and reduce the risk of pathological conditions while enhancing overall well-being. Nevertheless, there is a lack of clear information, and often, the claimed health benefits may not be properly substantiated by safety and efficacy information and in vitro and in vivo data, which can induce false expectations and miss the target for a product to be effective, as claimed...
February 12, 2018: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29414565/current-state-of-the-union-of-epilepsy-care-in-the-united-states-antiepileptic-drugs-an-introduction-to-the-connectors-project
#8
Joseph I Sirven, Patricia O Shafer, Linda Kalilani, Imane Wild, Jesse Fishman, Steve Owens
PURPOSE: How antiepileptic drugs (AEDs) are used in the United States (US) is one proxy public health indicator for the current state of epilepsy management. The use of phenytoin, other older AEDs, and newer AEDs may act as an indicator for the quality of epilepsy practice in addition to the current American Academy of Neurology quality measures. Data on AED used by states and populations can help identify which public health interventions are necessary to improve the status of epilepsy care...
February 1, 2018: Epilepsy & Behavior: E&B
https://www.readbyqxmd.com/read/29411268/a-phase-1-pharmacokinetic-study-of-cysteamine-bitartrate-delayed-release-capsules-following-oral-administration-with-orange-juice-water-or-omeprazole-in-cystinosis
#9
Danielle Armas, Robert J Holt, Nils F Confer, Gregg C Checani, Mohammad Obaidi, Yuli Xie, Meg Brannagan
INTRODUCTION: Cystinosis is a rare, metabolic, autosomal recessive, genetic lysosomal storage disorder characterized by an accumulation of cystine in various organs and tissues. Cysteamine bitartrate (CB) is a cystine-depleting aminothiol agent approved in the United States and Europe in immediate-release and delayed-release (DR) formulations for the treatment of nephropathic cystinosis in children and adults. It is recommended that CBDR be administered with fruit juice (except grapefruit juice) for maximum absorption...
February 6, 2018: Advances in Therapy
https://www.readbyqxmd.com/read/29408180/enhancing-patient-level-clinical-data-access-to-improve-trial-outcomes-promote-evidence-based-practice-and-incentivize-therapeutic-innovation
#10
Alice Fortunato, David W Grainger, Mohamed Abou-El-Enein
Clinical trials are crucial to determining the human safety and efficacy of new therapeutic interventions and innovations. Extraordinary amounts of human experiential data are generated over the course of any clinical drug or therapeutics trial. However, much of these data is never made publicly accessible, either archived openly in accessible formats or venues, published in peer-reviewed journals, or provided to researchers for analysis and scrutiny. Improved, reliable data sharing is essential to inform clinical outcomes and incentivize therapeutic improvements; this need, and the call and concept to improve clinical trial and human therapeutics data accessibility is not new...
January 30, 2018: Advanced Drug Delivery Reviews
https://www.readbyqxmd.com/read/29384023/prevalence-and-management-of-drug-related-problems-in-chronic-kidney-disease-patients-by-severity-level-a-subanalysis-of-a-cluster-randomized-controlled-trial-in-community-pharmacies
#11
Patricia Quintana-Bárcena, Anne Lord, Annie Lizotte, Djamal Berbiche, Lyne Lalonde
BACKGROUND: Drug-related problems (DRPs) are prevalent among chronic kidney disease (CKD) patients. However, little is known about their severity and management by community pharmacists. OBJECTIVES: To (a) describe the prevalence of DRPs by severity level in CKD patients and (b) assess the effect of a training-and-communication network program in nephrology (ProFiL) on these DRPs. METHODS: This is a secondary analysis of a cluster randomized controlled trial evaluating the effect of the ProFiL-program...
February 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29383980/optimizing-anti-vegf-treatment-outcomes-for-patients-with-neovascular-age-related-macular-degeneration
#12
Charles C Wykoff, W Lloyd Clark, Jared S Nielsen, Joel V Brill, Laurence S Greene, Cherilyn L Heggen
BACKGROUND: The introduction of anti-vascular endothelial growth factor (anti-VEGF) drugs to ophthalmology has revolutionized the treatment of neovascular age-related macular degeneration (nAMD). Despite this significant progress, gaps and challenges persist in the diagnosis of nAMD, initiation of treatment, and management of frequent intravitreal injections. Thus, nAMD remains a leading cause of blindness in the United States. OBJECTIVE: To present current knowledge, evidence, and expert perspectives on anti-VEGF therapies in nAMD to support managed care professionals and providers in decision making and collaborative strategies to overcome barriers to optimize anti-VEGF treatment outcomes among nAMD patients...
February 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29382036/botulinum-toxin-a-for-sialorrhoea-associated-with-neurological-disorders-evaluation-of-the-relationship-between-effect-of-treatment-and-the-number-of-glands-treated
#13
Domenico A Restivo, Mariangela Panebianco, Antonino Casabona, Sara Lanza, Rosario Marchese-Ragona, Francesco Patti, Stefano Masiero, Antonio Biondi, Angelo Quartarone
Background: Sialorrhoea and drooling are disabling manifestations of different neurological disorders. The aim of this study was to evaluate the effects of botulinum neurotoxin type A (BoNT/A) injection on hypersalivation in 90 patients with neurological diseases of different aetiologies, and to define the minimum number of injected salivary glands to reduce sialorrhoea. Determining the minimum number of glands that need to be engaged in order to have a significant reduction in drooling may be very useful for establishing the minimum total dosage of BoNT/A that may be considered effective in the treatment of hypersalivation...
January 27, 2018: Toxins
https://www.readbyqxmd.com/read/29379635/reducing-the-osteoporosis-treatment-gap-an-interview-with-ucb-s-pascale-richetta
#14
Pascale Richetta
Dr. Pascale Richetta is Executive Vice President and Head of the Bone Patient Value Unit at UCB (Brussels, Belgium). She joined UCB in 2016 following over 20 years' experience in the pharma and biotech industry. After completing her MD at the University of Poitiers (France), she spent time as vice president at Abbvie/Abbott and has also held positions at GlaxoSmithKline, Ipsen and Servier. Through the course of her career she acquired impressive commercial experience managing both traditional pharmaceuticals and complex biologics and her knowledge of markets around the world is key to helping UCB prepare for future product launches...
February 2018: Future Science OA
https://www.readbyqxmd.com/read/29370727/chimeric-antigen-receptor-t-cell-therapy-for-cancer-a-basic-research-oriented-perspective
#15
Chungyong Han, Byoung S Kwon
Chimeric antigen receptor (CAR) T cells have outstanding therapeutic potential for treating blood cancers. The prospects for this technology have accelerated basic research, clinical translation and Big Pharma's investment in the field of T-cell therapeutics. This interest has led to the discovery of key factors that affect CAR T-cell efficacy and play pivotal roles in T-cell immunology. Herein, we introduce advances in adoptive immunotherapy and the birth of CAR T cells, and review CAR T-cell studies that focus on three important features: CAR constructs, target antigens and T-cell phenotypes...
March 2018: Immunotherapy
https://www.readbyqxmd.com/read/29362772/pharma-art-abstract-medication-in-the-work-of-beverly-fishman
#16
Bonnie Pitman
No abstract text is available yet for this article.
January 23, 2018: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/29360284/amyloid-fibril-polymorphism-a-challenge-for-molecular-imaging-and-therapy
#17
Marcus Fändrich, Sofie Nyström, K Peter R Nilsson, Anja Böckmann, Harry LeVine, Per Hammarström
The accumulation of misfolded proteins (MP), both unique and common, for different diseases is central for many chronic degenerative diseases. In certain patients MP accumulation is systemic (e.g. TTR amyloid) and in others this is localized to a specific cell type (e.g. Alzheimer's disease). In neurodegenerative diseases, NDs, it is noticeable that the accumulation of MP progressively spreads throughout the nervous system. Our main hypothesis of this article is that MPs are not only markers but also active carriers of pathogenicity...
January 23, 2018: Journal of Internal Medicine
https://www.readbyqxmd.com/read/29343975/spotlight-on-midostaurin-in-the-treatment-of-flt3-mutated-acute-myeloid-leukemia-and-systemic-mastocytosis-design-development-and-potential-place-in-therapy
#18
REVIEW
Ellen Weisberg, Martin Sattler, Paul W Manley, James D Griffin
The Fms-like tyrosine kinase-3 (FLT3; fetal liver kinase-2; human stem cell tyrosine kinase-1; CD135) is a class III receptor tyrosine kinase that is normally involved in regulating the proliferation, differentiation, and survival of both hematopoietic cells and dendritic cells. Mutations leading it to be constitutively activated make it an oncogenic driver in ~30% of acute myeloid leukemia (AML) patients where it is associated with poor prognosis. The prevalence of oncogenic FLT3 and the dependency on its constitutively activated kinase activity for leukemia growth make this protein an attractive target for therapeutic intervention...
2018: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29341027/developing-deep-learning-applications-for-life-science-and-pharma-industry
#19
Daniel Siegismund, Vasily Tolkachev, Stephan Heyse, Beate Sick, Oliver Duerr, Stephan Steigele
Deep Learning has boosted artificial intelligence over the past 5 years and is seen now as one of the major technological innovation areas, predicted to replace lots of repetitive, but complex tasks of human labor within the next decade. It is also expected to be 'game changing' for research activities in pharma and life sciences, where large sets of similar yet complex data samples are systematically analyzed. Deep learning is currently conquering formerly expert domains especially in areas requiring perception, previously not amenable to standard machine learning...
January 16, 2018: Drug Research
https://www.readbyqxmd.com/read/29340313/treatment-of-severe-hyperkalemia-confronting-4-fallacies
#20
REVIEW
J Gary Abuelo
Severe hyperkalemia is a medical emergency that can cause lethal arrhythmias. Successful management requires monitoring of the electrocardiogram and serum potassium concentrations, the prompt institution of therapies that work both synergistically and sequentially, and timely repeat dosing as necessary. It is of concern then that, based on questions about effectiveness and safety, many physicians no longer use 3 key modalities in the treatment of severe hyperkalemia: sodium bicarbonate, sodium polystyrene sulfonate (Kayexalate [Concordia Pharmaceuticals Inc...
January 2018: KI Reports
keyword
keyword
7232
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"